amikacin has been researched along with Ventilator-Associated Pneumonia in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (8.57) | 29.6817 |
| 2010's | 23 (65.71) | 24.3611 |
| 2020's | 9 (25.71) | 2.80 |
| Authors | Studies |
|---|---|
| Dumas, JL; Köhler, T; Reinhardt, A; Ricou, B; Rohner, P; van Delden, C; Wood, P | 1 |
| Andreu, P; Barbier, F; Beduneau, G; Boulain, T; Cabrera, M; Dahyot-Fizelier, C; Ehrmann, S; Ferrandiere, M; Gregoire, N; Helms, J; Herbrecht, JE; Lacherade, JC; Landais, M; Lanotte, P; Lasocki, S; Le Pennec, D; Leclerc, M; Lu, Q; Merdji, H; Meziani, F; Muller, G; Nay, MA; Plantefeve, G; Quenot, JP; Respaud, R; Roux, D; Schnell, D; Seguin, P; Tavernier, E; Veber, B; Vecellio, L; Veinstein, A | 1 |
| Bahniuk, N; Dmytriiev, D; Dmytriiev, K; Levchenko, B; Melnychenko, M; Nazarchuk, O | 1 |
| Bayatinejad, G; Beigverdi, R; Emaneini, M; Halimi, S; Jabalameli, F; Salehi, M | 1 |
| Andreu, P; Azaïs, MA; Barbier, F; Beduneau, G; Benzekri, D; Chebib, N; Clere-Jehl, R; Dahyot-Fizelier, C; Demiselle, J; Ehrmann, S; Ferrandiere, M; Gandonnière, CS; Garot, D; Gouin, P; Gregoire, N; Herbrecht, JE; Heuzé-Vourc'h, N; Lacherade, JC; Landais, M; Lasocki, S; Lu, Q; Mercier, E; Merdji, H; Meziani, F; Nay, MA; Plantefève, G; Quenot, JP; Respaud, R; Roux, D; Saint-Martin, M; Schnell, D; Seguin, P; Tavernier, E; Veinstein, A; Zucman, N | 1 |
| Kalil, AC; Sweeney, DA | 1 |
| Alder, J; Bassetti, M; Boateng, F; Cao, B; Chastre, J; Corkery, K; Dhand, R; Kaye, KS; Lawatscheck, R; McLeroth, P; Nicolau, DP; Niederman, MS; Wang, C; Wood, GC; Wunderink, RG | 1 |
| Nambiar, S; Schumann, K; Walinsky, S | 1 |
| Du, B; Huang, HB; Qin, JP; Xu, Y; Zhou, H; Zhu, Y | 1 |
| Hu, B; Li, JG; Liu, C; Peng, ZY; Zhang, YT; Zhou, H; Zhou, Q | 1 |
| Shorr, AF; Zilberberg, MD | 1 |
| Borgatta, B; Gattarello, S; Imbiscuso, AT; Larrosa, MN; Lujàn, M; Mazo, CA; Rello, J | 1 |
| Abbassi, MM; Awdallah, FF; Hassan, NA; Sabry, NA | 1 |
| Kidd, JM; Kuti, JL; Nicolau, DP | 1 |
| Ahmadi, A; Azadbakht, S; Dianatkhah, M; Mojtahedzadeh, M; Najafi, A; Najmeddin, F; Rouini, MR; Shahrami, B; Sharifnia, H | 1 |
| Jacobs, FM | 1 |
| Schreiber, MP; Shorr, AF | 1 |
| Gilbert, DN | 1 |
| Antoniu, S; Azoicai, D | 1 |
| Abuan, T; Davies, A; Montgomery, AB; Tservistas, M; Vallance, S | 1 |
| Abuan, T; Flamm, RK; Montgomery, AB; Rhomberg, PR; Walters, KA | 1 |
| Armand-Lefèvre, L; Burdet, C; Couffignal, C; Foucrier, A; Laouénan, C; Massias, L; Mentré, F; Pajot, O; Wolff, M | 1 |
| Armand-Lefevre, L; Burdet, C; Couffignal, C; Da Silva, D; Foucrier, A; Laouénan, C; Lasocki, S; Massias, L; Mentec, H; Mentré, F; Pajot, O; Wolff, M | 1 |
| Farrell, DJ; Jones, RN; Rhomberg, PR; Sader, HS | 1 |
| Berra, L; Klompas, M; Zhang, C | 1 |
| Boulain, T; Darrouzain, F; Dequin, PF; Ehrmann, S; Garot, D; Paintaud, G; Petitcollin, A; Ternant, D; Vecellio, L | 1 |
| Badal, RE; Biedenbach, DJ; Giao, PT; Hung Van, P; Phuong, DM; Su Minh Tuyet, N; Thi Thanh Nga, T; Vu Trung, N | 1 |
| Boulain, T; Danker, W; Dimopoulos, G; Francois, B; Garot, D; Ischaki, E; Ivanyi, Z; János, G; Kollef, MH; Koura, F; Montgomery, AB; Ricard, JD; Roux, D; Rozgonyi, Z; Torres, A; Zakynthinos, E | 1 |
| Hasegawa, H; Izumikawa, K; Kaku, N; Kosai, K; Miyazaki, T; Morinaga, Y; Mukae, H; Takeda, K; Uno, N; Yanagihara, K | 1 |
| Chaudhury, A; Kalawat, U; Rani, AS; Sumant, S; Venkataramana, B; Verma, A | 1 |
| Boucher, BA; Croce, MA; Czosnowski, QA; Fabian, TC; Magnotti, LJ; Swanson, JM; Wood, GC | 1 |
| Aymard, G; Gutierrez, C; Liu, Z; Lu, Q; Rouby, JJ; Yang, J | 1 |
| Chastre, J; Corkery, K; Fink, JB; García, MS; Luyt, CE; Niederman, MS | 1 |
| Bernusset, S; Cattoen, C; Cuzon, G; Naas, T; Nordmann, P | 1 |
| Gilbert, D | 1 |
5 review(s) available for amikacin and Ventilator-Associated Pneumonia
| Article | Year |
|---|---|
Amikacin nebulization for the adjunctive therapy of gram-negative pneumonia in mechanically ventilated patients: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Amikacin; Anti-Bacterial Agents; Critical Care; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Length of Stay; Middle Aged; Nebulizers and Vaporizers; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Respiration, Artificial; Treatment Outcome | 2021 |
Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria.
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Clinical Trials as Topic; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Pneumonia, Ventilator-Associated; Sisomicin | 2018 |
Inhaled antibiotics for the treatment of pneumonia.
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Humans; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated | 2019 |
Novel amikacin inhaled formulation for the treatment of lower respiratory tract infections.
Topics: Administration, Inhalation; Amikacin; Animals; Anti-Bacterial Agents; Bacteria; Cystic Fibrosis; Humans; Liposomes; Pneumonia, Ventilator-Associated; Respiratory Tract Infections | 2013 |
Should Aerosolized Antibiotics Be Used to Treat Ventilator-Associated Pneumonia?
Topics: Administration, Inhalation; Amikacin; Animals; Anti-Bacterial Agents; Ceftazidime; Colistin; Humans; Pneumonia, Ventilator-Associated | 2016 |
11 trial(s) available for amikacin and Ventilator-Associated Pneumonia
| Article | Year |
|---|---|
Inhaled amikacin versus placebo to prevent ventilator-associated pneumonia: the AMIKINHAL double-blind multicentre randomised controlled trial protocol.
Topics: Administration, Inhalation; Amikacin; Double-Blind Method; Humans; Multicenter Studies as Topic; Pneumonia, Ventilator-Associated; Randomized Controlled Trials as Topic; Respiration, Artificial; Treatment Outcome | 2021 |
Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia.
Topics: Administration, Inhalation; Adult; Amikacin; Anti-Bacterial Agents; Critical Illness; Double-Blind Method; Humans; Pneumonia, Ventilator-Associated; Respiration, Artificial; Treatment Outcome | 2023 |
Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial.
Topics: Administration, Inhalation; Administration, Intravenous; Adult; Aged; Amikacin; Anti-Bacterial Agents; Double-Blind Method; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Gram-Negative Bacterial Infections; Hospitals; Humans; Male; Middle Aged; Placebos; Pneumonia, Ventilator-Associated; Prospective Studies; Standard of Care; Survival Analysis; Treatment Outcome; Young Adult | 2020 |
Aerosolized Amikacin as Adjunctive Therapy of Ventilator-associated Pneumonia Caused by Multidrug-resistant Gram-negative Bacteria: A Single-center Randomized Controlled Trial.
Topics: Administration, Inhalation; Aged; Amikacin; Anti-Bacterial Agents; Colistin; Double-Blind Method; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Humans; Intensive Care Units; Male; Middle Aged; Pneumonia, Ventilator-Associated | 2017 |
Nebulized Versus IV Amikacin as Adjunctive Antibiotic for Hospital and Ventilator-Acquired Pneumonia Postcardiac Surgeries: A Randomized Controlled Trial.
Topics: Administration, Inhalation; Adult; Amikacin; Cross Infection; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Multiple; Female; Gram-Negative Bacterial Infections; Heart Diseases; Humans; Infusions, Intravenous; Length of Stay; Male; Middle Aged; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Postoperative Complications; Prospective Studies; Treatment Outcome | 2018 |
A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow® inline nebulizer system in mechanically ventilated patients.
Topics: Administration, Inhalation; Adult; Aerosols; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Bronchitis; Double-Blind Method; Drug Combinations; Drug Monitoring; Equipment Design; Fosfomycin; Humans; Male; Middle Aged; Nebulizers and Vaporizers; Pneumonia, Ventilator-Associated; Respiration, Artificial; Tracheitis; Victoria | 2014 |
Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Critical Illness; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Pneumonia, Ventilator-Associated | 2015 |
A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia: IASIS Trial.
Topics: Administration, Inhalation; Adult; Aged; Amikacin; Anti-Bacterial Agents; APACHE; Chemotherapy, Adjuvant; Double-Blind Method; Female; Fosfomycin; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Pneumonia, Ventilator-Associated; Treatment Outcome | 2017 |
Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Ceftazidime; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Lung; Male; Middle Aged; Nebulizers and Vaporizers; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Tomography, X-Ray Computed | 2011 |
BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia.
Topics: Aerosols; Amikacin; Anti-Bacterial Agents; Body Fluids; Double-Blind Method; Female; Gram-Negative Bacterial Infections; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Respiration, Artificial; Trachea | 2012 |
"The truth, if it exists, is in the details".
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Doripenem; Humans; Imipenem; Pneumonia, Ventilator-Associated; Severity of Illness Index; Treatment Outcome | 2008 |
19 other study(ies) available for amikacin and Ventilator-Associated Pneumonia
| Article | Year |
|---|---|
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Drug Resistance, Bacterial; Humans; Longitudinal Studies; Pneumonia, Ventilator-Associated; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections | 2007 |
Adjunctive inhaled amikacin in infants with Ventilator-Associated Pneumonia optimizes the complex antimicrobial therapy: pilot study.
Topics: Administration, Inhalation; Amikacin; Aminoglycosides; Annexin A5; Anti-Bacterial Agents; Humans; Infant; Pilot Projects; Pneumonia, Ventilator-Associated | 2023 |
In Vitro antibiotic combinations of Colistin, Meropenem, Amikacin, and Amoxicillin/clavulanate against multidrug-resistant Klebsiella pneumonia isolated from patients with ventilator-associated pneumonia.
Topics: Amikacin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Colistin; Drug Synergism; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated | 2023 |
The last breath for inhaled antibiotics and VAP? Not so fast.
Topics: Amikacin; Anti-Bacterial Agents; Double-Blind Method; Humans; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Respiration, Artificial | 2020 |
FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs.
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Antifungal Agents; Cross Infection; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Liposomes; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Nitroimidazoles; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Sisomicin; United States; United States Food and Drug Administration | 2021 |
The Answer for Inhaled Antibiotics in Pneumonia Is Still Blowing in the Wind.
Topics: Amikacin; Anti-Bacterial Agents; Fosfomycin; Humans; Pneumonia, Ventilator-Associated; Ventilators, Mechanical | 2017 |
The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Case-Control Studies; Colistin; Drug Resistance, Multiple, Bacterial; Female; Humans; Immunocompromised Host; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Ventilators, Mechanical | 2017 |
Evaluation of Epithelial Lining Fluid Concentration of Amikacin in Critically Ill Patients With Ventilator-Associated Pneumonia.
Topics: Adult; Aged; Amikacin; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Critical Illness; Female; Humans; Lung; Male; Middle Aged; Pilot Projects; Pneumonia, Ventilator-Associated; Pulmonary Alveoli; Respiratory Mucosa | 2020 |
Nebulized Versus IV Amikacin: Systemic Antibiotics Treatment Modalities May Hamper Results.
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Humans; Pneumonia, Ventilator-Associated; Treatment Outcome | 2018 |
Nebulized Antibiotics for Multidrug-Resistant Ventilator-Associated Pseudomonas aeruginosa Pneumonia.
Topics: Amikacin; Anti-Bacterial Agents; Fosfomycin; Humans; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections | 2019 |
Amikacin-fosfomycin at a five-to-two ratio: characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics.
Topics: Amikacin; Anti-Bacterial Agents; Bacteria; DNA Mutational Analysis; Drug Combinations; Drug Interactions; Drug Resistance, Bacterial; Drug Synergism; Fosfomycin; Humans; Kinetics; Microbial Sensitivity Tests; Mutation; Pneumonia, Ventilator-Associated | 2014 |
Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Bacterial Load; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Ventilator-Associated; Prospective Studies; Treatment Outcome | 2015 |
Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia.
Topics: Amikacin; Anti-Bacterial Agents; Dibekacin; Enterobacter; Humans; Klebsiella; Microbial Sensitivity Tests; Pneumonia; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Staphylococcus aureus; Tobramycin | 2015 |
Pharmacokinetics of high-dose nebulized amikacin in ventilated critically ill patients.
Topics: Adult; Aerosols; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Critical Illness; Female; Humans; Male; Middle Aged; Pneumonia, Ventilator-Associated; Respiration, Artificial; Serum; Young Adult | 2016 |
Antimicrobial-resistant Pseudomonas aeruginosa and Acinetobacter baumannii From Patients With Hospital-acquired or Ventilator-associated Pneumonia in Vietnam.
Topics: Acinetobacter baumannii; Amikacin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Cross Infection; Doripenem; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gentamicins; Humans; Longitudinal Studies; Microbial Sensitivity Tests; Minocycline; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Tigecycline; Vietnam | 2016 |
Efficacy and pharmacokinetics of ME1100, a novel optimized formulation of arbekacin for inhalation, compared with amikacin in a murine model of ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Amikacin; Animals; Anti-Bacterial Agents; Dibekacin; Disease Models, Animal; Drug Compounding; Lung; Mice; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections | 2017 |
Antibiotic resistance & pathogen profile in ventilator-associated pneumonia in a tertiary care hospital in India.
Topics: Amikacin; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; India; Intensive Care Units; Klebsiella; Methicillin Resistance; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Ventilator-Associated; Pseudomonas; Staphylococcus aureus; Tertiary Care Centers; Vancomycin-Resistant Enterococci | 2016 |
Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia.
Topics: Acinetobacter baumannii; Adult; Aerosols; Amikacin; Anti-Bacterial Agents; APACHE; Colistin; Critical Illness; Drug Resistance, Multiple; Female; Glasgow Coma Scale; Gram-Negative Bacteria; Humans; Male; Middle Aged; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Retrospective Studies; Tobramycin; Treatment Outcome | 2009 |
First identification of blaIMI-1 in an Enterobacter cloacae clinical isolate from France.
Topics: Adult; Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Enterobacter cloacae; Enterobacteriaceae Infections; France; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; RNA, Ribosomal, 16S; Sequence Analysis, DNA; Tazobactam | 2012 |